Table 1.
Baseline (n=202) |
2-month (n=202) |
4-month (n=195) |
6-month (n=201) |
||||||
---|---|---|---|---|---|---|---|---|---|
mean | sd | mean | sd | mean | sd | mean | sd | ||
Predictors | |||||||||
ASI psychiatric | 0.30 | 0.16 | 0.28 | 0.17 | 0.26 | 0.17 | 0.25 | 0.18 | |
# psych symptoms | 1.77 | 1.19 | 1.78 | 1.28 | 1.56 | 1.20 | 1.47 | 1.29 | |
Outcomes | |||||||||
PDA from MA use c | 0.49 | 0.35 | 0.70 | 0.31 | 0.76 | 0.33 | 0.76 | 0.32 | |
ASI drug c | 0.23 | 0.09 | 0.18 | 0.10 | 0.16 | 0.10 | 0.16 | 0.10 | |
# of days used drugs c | 17.66 | 11.15 | 14.24 | 12.09 | 12.94 | 13.10 | 13.10 | 12.05 | |
# of days experienced drug problems c | 17.89 | 11.60 | 13.14 | 12.14 | 11.02 | 11.57 | 11.57 | 12.07 | |
How troubled by drug problems c | 3.05 | 1.14 | 2.33 | 1.50 | 2.20 | 1.48 | 2.14 | 1.56 | |
Importance of drug treatment c | 3.57 | 1.04 | 2.74 | 1.58 | 2.40 | 1.64 | 2.21 | 1.70 |
p < 0.05, paired t-test significance between baseline and the 2-month follow-up interview The items assessing troubled by drug problems and importance of drug treatment were assessed on a 5-point Likert scale